• Developmental SSRI Exposure and Motivation in Mice

  2026-10-05

  Cambre’s 2026 Columbia dissertation reports that developmental exposure to selective serotonin reuptake inhibitors produces persistent, selective deficits in effortful motivation in adolescent and adult mice, while reward liking and Pavlovian learning remain comparatively intact. Pharmacological antagonism and nucleus accumbens mu opioid receptor knockdown attenuated the motivational phenotype, identifying a circuit-level mechanism for further depression research rather than evidence for direct clinical translation.

• Molidustat and the Translational Logic of HIF Stabilization

  2026-10-05

  Molidustat (BAY85-3934) illustrates how HIF-PH inhibition can connect oxygen sensing, endogenous erythropoietin stimulation, and chronic kidney disease anemia. This thought-leadership analysis examines the mechanistic rationale, interprets findings from a cardiomyocyte study of VHL-mediated HIF-1α degradation, and outlines evidence-based priorities for translational researchers without overstating what current preclinical data demonstrate.

• Fulvestrant (ICI 182,780): Reading ERα Evidence

  2026-10-04

  Fulvestrant (ICI 182,780) is examined as both an ERα-directed research tool and an evidence-interpretation problem. This article connects MDM2 protein degradation, endocrine therapy resistance research, and estrogen signaling in immune recovery while defining the limits of cross-model conclusions.

• Fluoxetine HCl: Reading Motivation Data

  2026-10-03

  Fluoxetine HCl is more than a selective serotonin reuptake inhibitor: it is a useful probe for connecting transporter pharmacology with 5-HT2C signaling, plasticity, and reward behavior. This article explains how a 2026 Columbia dissertation separates motivational deficits from reward liking and learning while defining the limits of translational interpretation.

• IDH2, α-KG, and HIF-1α in Colorectal Cancer

  2026-10-02

  The reference study identifies elevated IDH2 as a metabolic driver of colorectal cancer progression, linking reductive citrate-cycle activity to α-ketoglutarate depletion, HIF-1α stabilization, glycolysis, and tumor growth. Its combined genetic, pharmacological, metabolic, and in vivo design provides a framework for testing how mitochondrial carbon flux influences hypoxia signaling and cancer-cell energetics.

• BRCA2, PARP1 Retention, and RAD51 Filament Protection

  2026-10-01

  A 2025 Nature study identifies PARP1 retention on resected DNA as a direct source of RAD51 filament instability during PARP inhibition and shows that full-length BRCA2 counteracts this effect. The findings clarify how BRCA2 status can influence PARP inhibitor response and provide a mechanistic framework for studying homologous recombination deficiency targeting.

• Hydroxycinnamic Acids Target COPII–STING Trafficking

  2026-10-01

  This study identifies the Sec24 B-site of the COPII coat complex as a molecular target of cinnamic, caffeic, and ferulic acids, linking cargo sorting to cGAS–STING-driven inflammation. Structural, cellular, and diabetic mouse experiments suggest that blocking STING trafficking from the endoplasmic reticulum to the Golgi can improve steatosis, glucose handling, and hepatic injury.

• Endothelial STING–JAK1 Signaling in Tumor Immunity

  2026-09-30

  The reference study identifies endothelial STING as an active regulator of tumor vessel normalization and CD8+ T-cell infiltration, rather than only a canonical upstream inducer of type I interferon. Its central mechanistic finding is that interferon signaling promotes a JAK1–STING interaction involving STING palmitoylation at Cys91, offering a framework for interpreting vascular and immune responses in cancer models.

• Lovastatin Assays: From Flux to Cell Fate

  2026-09-30

  Lovastatin is an HMG-CoA reductase inhibitor whose effects extend from mevalonate depletion to proliferation, apoptosis, and macrophage clearance phenotypes. This article presents an assay-design framework that connects those mammalian readouts with the mechanistic logic of recent KNUCKLES research while clearly separating evidence from hypothesis.

• Temozolomide Workflows for Glioma Research

  2026-09-29

  Build reproducible DNA-damage assays with Temozolomide, from DMSO stock preparation to ATRX-stratified glioma combination studies. The workflow connects controlled methylating stress with DNA repair mechanism research, chemotherapy resistance studies, and practical RTK/PDGFR inhibitor testing.

• Formononetin and Oxaliplatin Neurotoxicity

  2026-09-29

  This cell-based study identifies formononetin as a potential neuroprotective agent that reduces oxaliplatin-induced oxidative stress and neuronal apoptosis through Nrf2/HO-1-associated responses. Its central translational contribution is the preservation of anticancer activity in colorectal and cervical cancer models, although the findings remain preclinical and drug-specific.

• 3-Bromopyruvate Reverses Cetuximab Resistance

  2026-09-28

  Mu and colleagues show that combining 3-bromopyruvate with cetuximab suppresses cetuximab-resistant colorectal cancer models through coordinated ferroptosis, autophagy, and apoptosis. The study connects this response to restoration of FOXO3a signaling and provides a mechanistic framework for targeting resistant tumors with metabolic and death-pathway interventions.

• Silymarin: Identity Before Mechanism

  2026-09-28

  Silymarin research depends on knowing whether an observed effect belongs to a complex milk thistle extract or to a defined flavonolignan. This article connects silymarin chemistry to stronger assay interpretation across redox, cancer, metabolic, and exploratory antiviral studies.

• Thymoquinone in Doxorubicin Cardiotoxicity Research

  2026-09-27

  Explore how Thymoquinone can be used to investigate oxidative stress and ferroptosis-associated changes in doxorubicin cardiotoxicity models. This workflow connects cardiac-function measurements with biochemical, protein, and mitochondrial readouts—and separates published mouse doses from proposed cell-culture starting conditions.

• Catalpol for CUMS Neuroinflammation Research

  2026-09-26

  Use Catalpol to investigate how oxidative stress, NLRP3 inflammasome signaling, and neuroinflammation intersect in chronic-stress depression models. This workflow turns the reference study into practical assay choices while distinguishing its findings from broader, model-dependent applications.

8740 records 1/583 page Next 12345 下5页 Last page